Primary hyperoxaluria: insights into its clinical presentation, genetic mutations, and transplantation outcomes in a pediatric population in a tertiary care center.

backgroundPrimary hyperoxaluria (PH) is a rare inherited disorder characterized by excessive oxalate accumulation in blood and urine due to defects in glyoxylate metabolism, leading to significant clinical consequences. As genetic and phenotypic heterogeneity contribute to the morbidity of PH, this study examined the phenotypes and genotypes of PH among confirmed pediatric patients (< 18 years) diagnosed with PH at a tertiary care center in Saudi Arabia between 2014 and 2023.

resultsTwenty-one patients from 14 families, including 10 boys (47.6%) and 11 girls (52.4%), were included. Six families had more than one affected child. The median age at diagnosis was 36 months (interquartile range = 6-84). All but one patient had PH type 1 [due to alanine-glyoxylate aminotransferase gene variant (AGXT)], with the remaining patient having PH type 2 [associated with glyoxylate and hydroxypyruvate reductase gene (GRHPR)]. The most frequent variant in the AGXT gene was NM_000030.3: c.33dup (p.Lys12GlnfsTer156), which was detected in 38.1% of patients. High parental consanguinity (90.5%) and positive family history (81%) were notable. The major clinical manifestations were kidney stones (71.4%), nephrocalcinosis (47.6%), failure to thrive (38.1%), stage V chronic kidney disease (42.9%), and hematuria (33.3%). All patients received conservative management, in addition to liver transplantation in eight patients and combined liver-kidney transplantation in two patients. The mortality rate was 14.3% (3/21). AGXT variants such as NM_000030.3:c.481G > A(p.(Gly161Ser) and NM_000030.3: c.346G > A (p.(Gly116Arg) displayed potential trends with worse renal prognosis.

conclusionsPH type 1 is the predominant form of hyperoxaluria among Saudi patients. High consanguinity might contribute to its disease burden. Early diagnosis and intervention are critical for improving outcomes. Recently approved RNA interference-based therapies offer promising outcomes, potentially reducing the need for organ transplantation in patients with PH type 1. CLINICAL TRAIL NUMBER: Not applicable.